Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Irene Reina-Alfonso
Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
José Joaquín Domínguez-del-Castillo
Cardiovascular Pathology (GA09), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Fakhri Hassouneh
Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Carmen Gutiérrez-González
Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Alexander Batista-Duharte
Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Ana-Belén Pérez
Microbiology Service, Reina Sofia University Hospital of Cordoba/Maimonides Biomedical Research Institute (IMIBIC)/CIBERINFEC, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Fernando Sarramea
Severe Mental Illness-Health Alerts (GA12), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
María José Jaén-Moreno
Severe Mental Illness-Health Alerts (GA12), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Cristina Camacho-Rodríguez
Severe Mental Illness-Health Alerts (GA12), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Raquel Tarazona
Immunology Unit, Department of Physiology, University of Extremadura, 10003 Cáceres, Spain
Rafael Solana
Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Juan Molina
Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Alejandra Pera
Immunology and Allergy Group (GC01), Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba/Reina Sofia University Hospital, Av. Menendez Pidal s/n, 14004 Cordoba, Spain
Human cytomegalovirus (HCMV) is linked to age-related diseases like cardiovascular disease, neurodegenerative conditions, and cancer. It can also cause congenital defects and severe illness in immunocompromised individuals. Accurate HCMV seroprevalence assessment is essential for public health planning and identifying at-risk individuals. This is the first HCMV seroprevalence study conducted in the general Spanish adult population in 30 years. We studied HCMV seroprevalence and HCMV IgG antibody titres in healthy adult donors (HDs) and HCMV-related disease patients from 2010 to 2013 and 2020 to 2023, categorized by sex and age. We compared our data with 1993 and 1999 studies in Spain. The current HCMV seroprevalence among HDs in Spain is 73.48%. In women of childbearing age, HCMV seroprevalence has increased 1.4-fold in the last decade. HCMV-seropositive individuals comprise 89.83% of CVD patients, 69% of SMI patients, and 70.37% of COVID-19 patients. No differences in HCMV seroprevalence or HCMV IgG antibody titres were observed between patients and HDs. A significant reduction in Spanish HCMV seroprevalence among HDs was observed in 1993. However, women of childbearing age have shown an upturn in the last decade that may denote a health risk in newborns and a change in HCMV seroprevalence trends.
